Barclays Starts Amedisys (AMED) at Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts AMED Hot Sheet
Price: $100.99 --0%
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Barclays analyst Patrick Feeley initiates coverage on Amedisys (NASDAQ: AMED) with a Equalweight rating and a price target of $130.00.
For an analyst ratings summary and ratings history on Amedisys click here. For more ratings news on Amedisys click here.
Shares of Amedisys closed at $129.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Starts SGHC Limited (SGHC) at Equalweight
- Craig-Hallum Starts OraSure Technologies (OSUR) at Buy, PT $7
- Citi Starts Kewpie Corp (2809:JP) at Neutral
Create E-mail Alert Related Categories
New CoverageRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
